[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363627-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363627-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evolution-of-ar-and-non-ar-alterations-in-ctdna-of-patients-with-metastatic-prostate-cancer-phase-iii-alliance-a031201-trial-purpose-experimental-design-results-and-conclusions","Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer - Phase III Alliance A031201 Trial - Purpose, Experimental Design, Results, and Conclusions","","Androgen receptor pathway inhibitors (ARPI) such as enzalutamide and abiraterone are standard for metastatic castration-resistant prostate cancer, yet patients can show primary resistance and later develop secondary resistance. Using the targeted AR-ctDETECT cell-free DNA sequencing assay, the study longitudinally profiles tumor-derived genomic alterations in plasma from baseline and progression in phase III Alliance A031201 participants. Progression samples show higher cfDNA and ctDNA positivity with frequent AR alterations, rising AR copy-number gains and AR structural rearrangements plus enriched AR extrachromosomal DNA signatures.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evolution-of-ar-and-non-ar-alterations-in-ctdna-of-patients-with-metastatic-prostate-cancer-phase-iii-alliance-a031201-trial-purpose-experimental-design-results-and-conclusions/363627/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evolution-of-ar-and-non-ar-alterations-in-ctdna-of-patients-with-metastatic-prostate-cancer-phase-iii-alliance-a031201-trial-purpose-experimental-design-results-and-conclusions/363627.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in metastatic castration-resistant prostate cancer?","Question",{"text":63,"@type":64},"It examines how and why resistance to androgen receptor pathway inhibitors emerges, including both primary resistance and later acquired resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was ctDNA analyzed across treatment time points?",{"text":68,"@type":64},"The study used the targeted AR-ctDETECT cfDNA sequencing assay on plasma samples collected at baseline and at progression, focusing on patients with paired samples.",{"name":70,"@type":61,"acceptedAnswer":71},"What changes in ctDNA were observed at disease progression?",{"text":72,"@type":64},"Progression plasma samples showed elevated cfDNA levels and increased ctDNA positivity, with AR being the most frequently altered gene at both baseline and progression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363627,1790226793,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Evolution ofAR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial  \nJos C. Valentn Lpez1,2,3, Chenxi Yu4, Todd P. Knutson5, Anna Kobilka3, Jacqueline Lyman3,6, Siyuan Guo4, Bin Luo4, Sarah A. Munro5, Yingming Li3, Rakesh Heer7,8, Luke Gaughan8, Michael J. Morris9, Himisha Beltran10, Charles J. Ryan3,9,11, Emmanuel S. Antonarakis3,11, Andrew J. Armstrong12, Susan Halabi4, and Scott M. Dehm3,13,14  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis.\u003Cbr>Experimental Design: We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumorderived genomic alterations in plasma samples collected at baseline and progression from patients with mCRPC enrolled in the phase III Alliance A031201 trial of first-line enzalutamide with or without abiraterone. Analysis focused on 327 patients with paired samples available from both time points.\u003Cbr>Results: Progression plasma samples displayed elevated cfDNA levels and increased ctDNA positivity. AR was the most frequently altered gene at baseline and at progression.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | AR copy-number gains and AR genomic structural rearrangements (AR-GSR) increased at progression, along with copy-number losses of FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2 . An AR extrachromosomal DNA signature was enriched at progression and was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. Stratification by two extre mes of radiographic progression-free survival revealed preferential accumulation of AR alterationsin patients with delayed progression and a higher burden of non-AR alterations in patients with rapid progression.\u003Cbr>Conclusions: AR alterations in ctDNA accumulate at progression in patients with mCRPC treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanismsand inform precision therapy in advanced prostate cancer.\u003Cbr>See related commentary by Chauhan et al., p. 2323 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nProstate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related death among men in the United States (1) . Most prostate cancer tumors rely on androgensand androgen receptor (AR) driven transcriptional activity for growth and survival (2) . Accordingly, androgen deprivation therapy (ADT) remains the foundation of first-line treatment for advanced disea","cbCaisKisb7kh5IM","https://ap.wps.com/l/cbCaisKisb7kh5IM","pdf",3278317,15,"English","# Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction\n## Androgen signaling and treatment resistance","[{\"question\":\"What problem does the study address in metastatic castration-resistant prostate cancer?\",\"answer\":\"It examines how and why resistance to androgen receptor pathway inhibitors emerges, including both primary resistance and later acquired resistance.\"},{\"question\":\"How was ctDNA analyzed across treatment time points?\",\"answer\":\"The study used the targeted AR-ctDETECT cfDNA sequencing assay on plasma samples collected at baseline and at progression, focusing on patients with paired samples.\"},{\"question\":\"What changes in ctDNA were observed at disease progression?\",\"answer\":\"Progression plasma samples showed elevated cfDNA levels and increased ctDNA positivity, with AR being the most frequently altered gene at both baseline and progression.\"}]","Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer - Phase III Alliance A031201 Trial - Purpose, Experimental Design, Results, and Conclusions | PDF",1790152230,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91be899fd7b6177148bc0c3685881d6c.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c2ebb0205d35d7fe8d6231199101cb6.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ce116020ea1481bf86b6f2e91951934.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a08a9c74a3f38c28ad095512e343903.webp",980,1311]